Administrative Core The Lung Cancer SPORE Administrative Core provides scientific and administrative oversight for all of the SPORE Projects and Cores and the Developmental Research (DRP) and Career Enhancement (CEP) Programs. It also provides the main interface with patient advocates, NCI program staff, external and internal advisory boards, other Lung Cancer SPOREs, and other collaborating institutions. The SPORE Administrative Core is co-Directed by the SPORE MPIs Drs. John D. Minna and David E. Gerber at UTSW, and Drs. Jack A. Roth, and John V. Heymach at MDACC. The MPI plan details how they will work together and which aspects of the SPORE administration they will focus on. As part of a planned transition, Drs. Gerber and Heymach will assume full responsibility for the Administrative Core in years 3-5.
Specific Aims for the SPORE Administrative Core A are: 1. Direct the overall scientific quality and administrative management of the SPORE and ensure effective communication between SPORE investigators and Patient Advocates; facilitate integration of Research Projects and Cores within and between UTSW and MDACC; encourage and facilitate multidisciplinary collaborations and cooperation (including Patient Advocates), as well as data and resource sharing. 2. Prepare budgets, monitor budget expenditures, and implement corrective actions to stay within budget. 3. Coordinate all SPORE investigator meetings, including monthly SPORE works in progress (WIPs) videoconference/WebEx meetings, and Internal and External Advisory board meetings. 4. Coordinate access to SPORE Core resources and oversee data quality control and validation determined by review of the Data Sciences Core. 5. Ensure implementation of all federal, state, and institutional regulatory compliances. 6. Oversee SPORE DRP and CEP activities by advertising DRP and CEP grant opportunities, and conducting DRP and CEP grant review processes to ensure identification of the projects with the combination of the best science, innovation, and potential for clinical translation; work with DRP and CEP applicants to help them use SPORE resources and refine their projects for optimum translational potential, which will include identification of qualified mentors for DRP and CEP awardees; establish and carry out policies for recruitment of women and minorities to be involved scientifically in the SPORE and DRP and CEPs. 7. Enhance recruitment of women and minority patients to participate in SPORE-related clinical trials. 8. Encourage and facilitate horizontal and vertical collaboration of SPORE discoveries and investigators both within UTSW and MDACC and with other institutions. 9. Coordinate and maintain institutional commitments to the SPORE at UTSW and MDACC. 10. Communicate and consult with the NCI program director frequently to ensure adherence to all reporting requirements, including high-quality progress reports. 11. Coordinate and facilitate SPORE interactions with pharmaceutical and biotech industry partners. 12. Coordinate and facilitate Patient Advocate involvement in the SPORE. 13. Coordinate and facilitate resolution of scientific disputes.

Public Health Relevance

Administrative Core (Core A) Project Narrative The Lung Cancer SPORE Administrative Core provides scientific and administrative oversight for all of the SPORE Projects and Cores and the Developmental Research and Career Enhancement Programs. It also provides the main interface with patient advocates, NCI program staff, external and internal advisory boards, other Lung Cancer SPOREs, and other collaborating institutions.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA070907-21A1
Application #
10023862
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2020-09-01
Budget End
2021-08-31
Support Year
21
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Texas Sw Medical Center Dallas
Department
Type
DUNS #
800771545
City
Dallas
State
TX
Country
United States
Zip Code
75390
Mender, Ilgen; LaRanger, Ryan; Luitel, Krishna et al. (2018) Telomerase-Mediated Strategy for Overcoming Non-Small Cell Lung Cancer Targeted Therapy and Chemotherapy Resistance. Neoplasia 20:826-837
Gong, Ke; Guo, Gao; Gerber, David E et al. (2018) TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer. J Clin Invest 128:2500-2518
Wang, Jacqueline F; Pu, Xingxiang; Zhang, Xiaoshan et al. (2018) Variants with a low allele frequency detected in genomic DNA affect the accuracy of mutation detection in cell-free DNA by next-generation sequencing. Cancer 124:1061-1069
Rashdan, Sawsan; Minna, John D; Gerber, David E (2018) Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy. Lancet Respir Med 6:472-478
Pierzynski, Jeanne A; Ye, Yuanqing; Lippman, Scott M et al. (2018) Socio-demographic, Clinical, and Genetic Determinants of Quality of Life in Lung Cancer Patients. Sci Rep 8:10640
Akbay, Esra A; Kim, James (2018) Autochthonous murine models for the study of smoker and never-smoker associated lung cancers. Transl Lung Cancer Res 7:464-486
Zhang, Wei; Girard, Luc; Zhang, Yu-An et al. (2018) Small cell lung cancer tumors and preclinical models display heterogeneity of neuroendocrine phenotypes. Transl Lung Cancer Res 7:32-49
Tan, Xiaochao; Banerjee, Priyam; Liu, Xin et al. (2018) The epithelial-to-mesenchymal transition activator ZEB1 initiates a prometastatic competing endogenous RNA network. J Clin Invest 128:1267-1282
McMillan, Elizabeth A; Ryu, Myung-Jeom; Diep, Caroline H et al. (2018) Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer. Cell 173:864-878.e29
Walser, Tonya C; Jing, Zhe; Tran, Linh M et al. (2018) Silencing the Snail-Dependent RNA Splice Regulator ESRP1 Drives Malignant Transformation of Human Pulmonary Epithelial Cells. Cancer Res 78:1986-1999

Showing the most recent 10 out of 1059 publications